Magellan Asset Management Ltd Makes New $126.35 Million Investment in Medtronic PLC $MDT

Magellan Asset Management Ltd purchased a new stake in Medtronic PLC (NYSE:MDT) in the 3rd quarter, Holdings Channel.com reports. The firm purchased 1,326,614 shares of the medical technology company’s stock, valued at approximately $126,347,000. Medtronic makes up 1.5% of Magellan Asset Management Ltd’s holdings, making the stock its 27th largest position.

Several other institutional investors and hedge funds have also recently bought and sold shares of MDT. Vanguard Group Inc. boosted its stake in Medtronic by 1.5% in the second quarter. Vanguard Group Inc. now owns 126,909,406 shares of the medical technology company’s stock valued at $11,062,693,000 after acquiring an additional 1,895,165 shares during the period. Geode Capital Management LLC lifted its holdings in shares of Medtronic by 1.1% in the 2nd quarter. Geode Capital Management LLC now owns 28,227,006 shares of the medical technology company’s stock worth $2,448,699,000 after purchasing an additional 310,684 shares during the last quarter. Bank of New York Mellon Corp boosted its position in Medtronic by 0.9% during the 3rd quarter. Bank of New York Mellon Corp now owns 21,468,260 shares of the medical technology company’s stock valued at $2,044,637,000 after purchasing an additional 192,410 shares during the period. Massachusetts Financial Services Co. MA boosted its holdings in shares of Medtronic by 0.5% during the third quarter. Massachusetts Financial Services Co. MA now owns 21,086,499 shares of the medical technology company’s stock valued at $2,008,278,000 after acquiring an additional 98,220 shares during the period. Finally, Invesco Ltd. increased its holdings in shares of Medtronic by 3.9% in the 2nd quarter. Invesco Ltd. now owns 17,647,149 shares of the medical technology company’s stock worth $1,538,302,000 after acquiring an additional 666,557 shares during the period. Institutional investors and hedge funds own 82.06% of the company’s stock.

More Medtronic News

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: MiniMed priced its U.S. IPO at $25–$28 per share (28M shares) targeting about $784M — a clear step toward separating Medtronic’s diabetes business; investors will watch the sale size, Medtronic’s post‑IPO stake and how proceeds are used (value‑unlock thesis). Medtronic’s MiniMed prices IPO at up to $784M
• Positive Sentiment: MiniMed formally launched an IPO roadshow and lists an expected pricing date (investor presentation shows March 5), accelerating the timeline for the separation and potential corporate simplification. MiniMed announces launch of IPO roadshow
• Positive Sentiment: Regulatory/innovation wins: Medtronic secured a CE mark for next‑gen GI Genius module and ColonPRO software — product approvals support durable revenue streams in GI/diagnostics. Medtronic wins CE mark for next-gen GI Genius module, ColonPRO software
• Neutral Sentiment: Corporate sustainability and packaging improvements were highlighted in a press release — positive for ESG positioning but unlikely to move near‑term earnings. Improving Sustainability in Packaging & Products
• Neutral Sentiment: Industry and leadership commentary (including former Medtronic CEO Bill George speaking on policy) and trade/tariff debate may affect broader healthcare sentiment but are not direct catalysts for MDT. Trump’s State of the Union: What business leaders want to hear
• Negative Sentiment: Analyst moves: Truist trimmed its price target on MDT (from $107 to $103) while staying at Hold — signaling limited near‑term upside and likely contributing to selling pressure. Medtronic plc (MDT) Gains Momentum Through Diabetes and Cardiovascular Operations
• Negative Sentiment: Market caution: broader market headlines (AI‑job concerns, macro policy uncertainty) have pressured risk assets; with MDT’s spin‑off in play, investors may be trimming positions. Goldman Sachs warns AI-fueled layoffs could raise the unemployment rate this year: Chart

Analyst Upgrades and Downgrades

MDT has been the subject of a number of analyst reports. Daiwa Securities Group boosted their target price on shares of Medtronic from $104.00 to $117.00 and gave the company a “buy” rating in a research note on Tuesday, November 25th. JPMorgan Chase & Co. lowered their target price on Medtronic from $105.00 to $100.00 and set a “neutral” rating on the stock in a research report on Wednesday, February 18th. CICC Research began coverage on Medtronic in a research note on Friday, January 30th. They set an “outperform” rating on the stock. Wells Fargo & Company initiated coverage on Medtronic in a research note on Friday, January 30th. They issued an “overweight” rating and a $114.00 price target for the company. Finally, Leerink Partners lowered their price objective on shares of Medtronic from $120.00 to $119.00 and set an “outperform” rating on the stock in a research note on Wednesday, February 18th. One research analyst has rated the stock with a Strong Buy rating, fifteen have given a Buy rating and ten have issued a Hold rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $110.84.

Medtronic Stock Down 1.8%

Shares of NYSE:MDT opened at $96.85 on Wednesday. The firm has a 50 day simple moving average of $99.01 and a 200 day simple moving average of $96.83. The company has a market cap of $124.16 billion, a PE ratio of 26.98, a price-to-earnings-growth ratio of 2.48 and a beta of 0.71. Medtronic PLC has a 52 week low of $79.55 and a 52 week high of $106.33. The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.80 and a current ratio of 2.42.

Medtronic (NYSE:MDT) last issued its quarterly earnings results on Tuesday, February 17th. The medical technology company reported $1.36 earnings per share for the quarter, beating analysts’ consensus estimates of $1.34 by $0.02. Medtronic had a return on equity of 14.88% and a net margin of 13.00%.The business had revenue of $9.02 billion for the quarter, compared to the consensus estimate of $8.89 billion. During the same quarter in the previous year, the company posted $1.38 earnings per share. Medtronic’s revenue for the quarter was up 5.8% compared to the same quarter last year. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. As a group, research analysts expect that Medtronic PLC will post 5.46 earnings per share for the current year.

Medtronic Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Friday, January 16th. Shareholders of record on Friday, December 26th were paid a dividend of $0.71 per share. The ex-dividend date of this dividend was Friday, December 26th. This represents a $2.84 dividend on an annualized basis and a dividend yield of 2.9%. Medtronic’s dividend payout ratio (DPR) is 79.11%.

About Medtronic

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).